KRAS and metastatic colorectal cancer: A clinical trial based on 76 colorectal cancer patients also confirmed that Adagrasib (an oral small molecule inhibitor of mutant KRAS G12C protein) had antitumor activity in patients with metastatic colorectal cancer [46].